Pricing Log in Create free account
Friday 6 November 2026 Export BNTX’s income statement to Excel — free account

BioNTech SE Sponsored ADR

BNTX Healthcare Biotechnology

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.

Revenue
−16.4%
EPS
+708.4%
Free cash flow
−123.8%
Total debt
+44.4%

Quarter to September 2026, against a year earlier

86.95 1.09 +1.27%
Market cap
$21.6B
P/E
0.0×
Fwd P/E
−13.5×
Dividend yield
—
F-score
4/9
Altman Z
n/a
Beneish M
−2.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 81.32
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — 1 — — — — 9 4 —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 21,570.00
Revenue ttm 2,727.80
Net income ttm (1,613.13)
Free cash flow ttm (524.10)
Net debt Q (16,457.69)
Valuation
P/E 0.00
Forward P/E (13.50) (negative: loss-making)
Price / sales 7.88
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.05
Financial health
Current ratio Q 8.55 (at or above 1.5: strong)
Debt / equity Q 0.02 (at or below 0.5: strong)
Interest coverage Q 15.06
Growth
Revenue growth Q −16.42% (below 0%: shrinking)
Operating income growth Q +362.44% (above 0%: growing)
EPS, this year −21.21% (below 0%: weak)
EPS, next year A +1.44%
Revenue, next year A −39.26% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +3.38%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.8×, against a ten-year median of 2.2×; over the ten years it ranged from 0.8× in 2024 to 153× in 2020.
P/S against its own 10 years 63.47%
10-year low 10-year high
P/B against its own 10 years 11.14%
10-year low 10-year high
EV/Sales against its own 10 years 44.75%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 17,911 18,162 16,832 16,872
Receivables 2,527 1,638 1,105 910
Inventory 387 307 125 75
Other 309 241 206 173
21,134 20,347 18,268 18,041
2023 2024 2025 Q'26
Payables 383 462 605 602
ST’ Debt 30 43 59 120
Other 1,259 2,221 1,685 1,370
2,241 2,730 2,424 2,110

Compound Annual Growth %

10y 5y 3y
Sales — 42.58% (43.74%)
Cash Flow — 0.00% (66.96%)
Earnings — 0.00% 0.00%
Book Value — 69.23% 0.97%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 1.09 Actual 2.03

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2025 −0.22 −0.38 Miss by 0.16
Mar 2026 −2.52 −2.28 Beat by 0.24
Jun 2026 −2.68 −2.58 Beat by 0.10
Sep 2026 1.09 2.03 Beat by 0.94
Dec 2026 −1.18 — Reports 9 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (2.46) (3.77) 0.84 — —
’25 (1.82) (1.82) (0.14) (1.46) (5.32)
’24 (1.42) (3.62) 0.89 1.15 (3.00)
’23 2.20 (0.86) 0.73 2.05 4.15
’22 15.98 7.31 7.04 9.46 39.80
’21 5.29 12.98 14.56 13.93 46.89
’20 (0.26) (0.42) (1.03) 1.87 0.07
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 138 123 1,484 — —
’25 193 296 1,775 983 3,247
’24 204 139 1,369 1,266 2,977
’23 1,371 183 974 1,605 4,133
’22 7,154 3,402 3,486 4,197 18,238
’21 2,470 6,396 7,178 6,407 22,451
’20 31 46 79 396 551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (493) 15 (145) — —
’25 (822) 103 891 345 516
’24 (344) 1,755 (673) (513) 225
’23 (727) 4,772 875 893 5,813
’22 4,545 3,936 4,359 1,465 14,305
’21 (375) (121) 1,780 (232) 1,053
’20 (60) (17) (230) 292 (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (583) (44) (197) — —
’25 (1,473) 18 828 301 (326)
’24 (493) 1,604 (770) (605) (263)
’23 (786) 4,434 712 691 5,050
’22 4,477 3,859 4,284 1,303 13,923
’21 (409) (157) 1,733 (293) 874
’20 (70) (36) (255) 249 (112)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 69 151 122 551 22,451 18,238 4,133 2,977 3,247 2,728 +61.8% 1,972 1,997 2,527 (8.0%)
Gross margin, % — 68.12 89.27 84.01 87.70 84.66 82.70 84.29 80.32 77.64 74.59 +9.5 pt
EBT — (97) (56) (201) (167) 17,801 13,648 1,284 (733) (1,189) (1,699) +36.8%
EBT margin, % — (140.58) (37.36) (165.25) (30.23) 79.29 74.83 31.06 (24.63) (36.61) (62.29) +104.0 pt
Net income — 0 (56) (201) (167) 17,801 13,648 1,284 (733) (1,189) (1,613) n/m
Per share, $
Per share, $ Revenue — 7.67 0.79 0.58 2.34 92.01 74.96 17.18 12.38 13.43 10.94 +7.3%
Earnings — (10.43) (0.30) (0.95) 0.07 49.91 40.87 4.19 (3.00) (5.32) (6.84) (8.1%)
Cash flow — (6.56) (0.36) (1.05) (0.07) 4.31 58.80 24.16 0.93 2.13 (1.11) n/m
Capex — 0.00 (0.42) (0.38) (0.41) (0.73) (1.57) (3.17) (2.03) (3.48) (0.99) n/m
Free cash flow — (6.56) (0.78) (1.43) (0.47) 3.58 57.23 20.99 (1.10) (1.35) (2.10) (17.9%)
Book value — (6.56) 1.65 2.61 6.66 57.67 86.85 91.07 87.37 89.99 81.76 n/m
Shares, m — 9 191 211 235 244 243 241 240 242 249 +50.9%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 509.50 5.19 3.59 27.07 0.00 0.00 0.00 60.6
P/S — 0.00 0.00 0.00 34.84 2.80 1.98 6.54 9.20 7.09 7.88 6.9
P/B — 6.61 6.61 15.73 12.25 4.47 1.71 1.23 1.30 1.06 1.05 5.7
EV/Sales — 0.00 0.00 0.00 32.54 2.71 1.18 2.26 3.19 2.00 1.84 4.9
EV/FCF — 0.00 0.00 0.00 (160.68) 69.54 1.55 1.85 (36.10) (19.85) (9.60) (16.0)
Cash, $m
Cash, $m Operating cash flow — (59) (69) (222) (15) 1,053 14,305 5,813 225 516 (277) n/m
Capex — (65) (79) (80) (96) (178) (382) (764) (488) (842) (247) +37.7%
Free cash flow — (59) (148) (302) (112) 874 13,923 5,050 (263) (326) (524) +23.8%
Balance, $m
Balance, $m Working capital — 35 381 473 1,212 13,713 19,988 18,893 17,617 15,844 15,931 +114.8%
Net debt — (145) (422) (504) (1,265) (2,097) (14,595) (17,674) (17,886) (16,530) (16,458) +80.8%
Shareholders’ equity — (59) 315 553 1,567 14,071 21,131 21,912 21,005 21,750 20,386 n/m
Returns, %
Returns, % ROA — (16.22) (14.71) (24.10) 0.98 113.92 45.96 4.07 (2.92) (5.22) (7.22) +11.0 pt
ROIC — 0.00 0.00 (262.39) (19.47) 94.38 127.38 11.02 (28.51) (19.03) (34.28) (19.0) pt
ROE — (79.18) (44.25) (46.21) 1.64 155.73 56.47 4.68 (3.35) (6.01) (8.29) +73.2 pt
People
People Employees — — 1,179 1,310 1,941 3,082 4,530 6,133 6,772 7,807 — +31.0%
Revenue/emp, $m — 0.00 0.13 0.09 0.28 7.28 4.03 0.67 0.44 0.42 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

BioNTech SE Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GMAB Genmab A/S Sponsored ADR $31.5B 41.7× 47.3× +24.86% (above 0%: growing) −9.26% (below 0%: shrinking) −7.69% (below 0%: shrinking) 92.73% 32.47% Compare
ROIV Roivant Sciences Ltd. $26.5B — (loss-making) — (loss-making) −33.55% (below 0%: shrinking) n/m −29.99% (below 0%: shrinking) 80.31% (25,380.93%) Compare
INCY Incyte Corporation $24.1B 56.3× 55.6× +14.00% (above 0%: growing) n/m −232.97% (below 0%: shrinking) 93.02% (45.49%) Compare
INSM Insmed, Inc. $23.9B — (loss-making) — (loss-making) +268.43% (above 0%: growing) n/m +81.06% (above 0%: growing) 85.09% (17.04%) Compare
BNTX BioNTech SE Sponsored ADR $21.6B — (loss-making) — (loss-making) −16.42% (below 0%: shrinking) n/m −123.82% (below 0%: shrinking) 91.99% 9.70%
ALNY Alnylam Pharmaceuticals, Inc. $21.0B 7.9× 13.5× +16.74% (above 0%: growing) +747.64% (above 0%: growing) −4.76% (below 0%: shrinking) 75.19% 23.72% Compare
EXEL Exelixis, Inc. $16.8B 19.9× 20.2× +10.19% (above 0%: growing) +22.22% (above 0%: growing) −4.83% (below 0%: shrinking) 96.02% 40.75% Compare
ASND Ascendis Pharma A/S $16.6B 18.3× 15.4× +119.88% (above 0%: growing) n/m +2,335.93% (above 0%: growing) 91.85% 64.98% Compare
BBIO BridgeBio Pharma, Inc. $14.5B — (loss-making) — (loss-making) +192.60% (above 0%: growing) n/m +60.46% (above 0%: growing) 94.21% (3.30%) Compare
Median of peers $22.4B 19.9× 20.2× +20.80% +22.22% −4.80% 92.29% 10.21%

All 621 Biotechnology stocks →

BioNTech SE Sponsored ADR (BNTX) Latest News

3 Nov

Impact 3 · · Simply Wall St.
Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat transcript
Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · Zacks

28 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Zacks

27 Oct

Impact 3 · · 24/7 Wall St.

26 Oct

Impact 3 · · 24/7 Wall St.
Impact 3 · · GlobeNewswire

25 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 4 · · GlobeNewswire

22 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · Simply Wall St.

21 Oct

Impact 3 · · Zacks

20 Oct

Impact 3 · · GlobeNewswire

19 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

17 Oct

Impact 4 · · Simply Wall St.

13 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Investing.com
Impact 3 · · Simply Wall St.
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

10 Oct

Impact 3 · · Simply Wall St.

7 Oct

Impact 4 · · Simply Wall St.

26 Sep

Impact 4 · · Simply Wall St.

16 Sep

Impact 4 ·

15 Sep

Impact 4 ·

BNTX metrics, ten years each

stockrow.com/BNTX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com